BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Bilimoria KY, Bentrem DJ, Ko CY, Stewart AK, Winchester DP, Talamonti MS. National failure to operate on early stage pancreatic cancer. Ann Surg. 2007;246:173-180. [PMID: 17667493 DOI: 10.1097/sla.0b013e3180691579] [Cited by in Crossref: 354] [Cited by in F6Publishing: 143] [Article Influence: 23.6] [Reference Citation Analysis]
Number Citing Articles
1 Riner AN, Underwood PW, Yang K, Herremans KM, Cameron ME, Chamala S, Qiu P, George TJ, Permuth JB, Merchant NB, Trevino JG. Disparities in Pancreatic Ductal Adenocarcinoma-The Significance of Hispanic Ethnicity, Subgroup Analysis, and Treatment Facility on Clinical Outcomes. Cancer Med 2020;9:4069-82. [PMID: 32285629 DOI: 10.1002/cam4.3042] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
2 Hurwitz HI, Uppal N, Wagner SA, Bendell JC, Beck JT, Wade SM, Nemunaitis JJ, Stella PJ, Pipas JM, Wainberg ZA. Randomized, Double-Blind, Phase II Study of Ruxolitinib or Placebo in Combination With Capecitabine in Patients With Metastatic Pancreatic Cancer for Whom Therapy With Gemcitabine Has Failed. J Clin Oncol. 2015;33:4039-4047. [PMID: 26351344 DOI: 10.1200/jco.2015.61] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
3 Katz MH, Hu CY, Fleming JB, Pisters PW, Lee JE, Chang GJ. Clinical calculator of conditional survival estimates for resected and unresected survivors of pancreatic cancer. Arch Surg 2012;147:513-9. [PMID: 22351874 DOI: 10.1001/archsurg.2011.2281] [Cited by in Crossref: 28] [Cited by in F6Publishing: 32] [Article Influence: 2.8] [Reference Citation Analysis]
4 Huang P, Zhong XY, Xu Y, Cui YF. Role of neoadjuvant therapy and adjuvant therapy in treatment of pancreatic cancer. Shijie Huaren Xiaohua Zazhi 2013; 21(14): 1292-1296 [DOI: 10.11569/wcjd.v21.i14.1292] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
5 Schlitter AM, Esposito I. Definition of microscopic tumor clearance (r0) in pancreatic cancer resections. Cancers (Basel). 2010;2:2001-2010. [PMID: 24281214 DOI: 10.3390/cancers2042001] [Cited by in Crossref: 51] [Cited by in F6Publishing: 47] [Article Influence: 4.3] [Reference Citation Analysis]
6 Gong YF, Zhou QB, Liao YD, Mai C, Chen TJ, Tang YQ, Chen RF. Optimized construction of MUC1-VNTRn DNA vaccine and its anti-pancreatic cancer efficacy. Oncol Lett 2017;13:2198-206. [PMID: 28454381 DOI: 10.3892/ol.2017.5717] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
7 Roth S, Springfeld C, Diener MK, Tjaden C, Knebel P, Klaiber U, Michalski CW, Mieth M, Jäger D, Büchler MW, Hackert T. Protocol of a prospective, monocentric phase I/II feasibility study investigating the safety of multimodality treatment with a combination of intraoperative chemotherapy and surgical resection in locally confined or borderline resectable pancreatic cancer: the combiCaRe study. BMJ Open 2019;9:e028696. [PMID: 31434770 DOI: 10.1136/bmjopen-2018-028696] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 David M, Lepage C, Jouve JL, Jooste V, Chauvenet M, Faivre J, Bouvier AM. Management and prognosis of pancreatic cancer over a 30-year period. Br J Cancer. 2009;101:215-218. [PMID: 19568238 DOI: 10.1038/sj.bjc.6605150] [Cited by in Crossref: 50] [Cited by in F6Publishing: 50] [Article Influence: 3.8] [Reference Citation Analysis]
9 Woodmass J, Lipschitz J, McKay A. Physician attitudes and treatment patterns for pancreatic cancer. World J Surg Oncol 2011;9:21. [PMID: 21310086 DOI: 10.1186/1477-7819-9-21] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.2] [Reference Citation Analysis]
10 Wei AC, Urbach DR, Devitt KS, Wiebe M, Bathe OF, McLeod RS, Kennedy ED, Baxter NN. Improving quality through process change: a scoping review of process improvement tools in cancer surgery. BMC Surg 2014;14:45. [PMID: 25038587 DOI: 10.1186/1471-2482-14-45] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
11 Hatzaras I, Schmidt C, Klemanski D, Muscarella P, Melvin WS, Ellison EC, Bloomston M. Pancreatic resection in the octogenarian: a safe option for pancreatic malignancy. J Am Coll Surg. 2011;212:373-377. [PMID: 21227721 DOI: 10.1016/j.jamcollsurg.2010.10.015] [Cited by in Crossref: 78] [Cited by in F6Publishing: 62] [Article Influence: 7.1] [Reference Citation Analysis]
12 O’Neill CB, Atoria CL, O’Reilly EM, LaFemina J, Henman MC, Elkin EB. Costs and trends in pancreatic cancer treatment. Cancer. 2012;118:5132-5139. [PMID: 22415469 DOI: 10.1002/cncr.27490] [Cited by in Crossref: 63] [Cited by in F6Publishing: 55] [Article Influence: 6.3] [Reference Citation Analysis]
13 Handgraaf HJ, Boonstra MC, Van Erkel AR, Bonsing BA, Putter H, Van De Velde CJ, Vahrmeijer AL, Mieog JS. Current and future intraoperative imaging strategies to increase radical resection rates in pancreatic cancer surgery. Biomed Res Int 2014;2014:890230. [PMID: 25157372 DOI: 10.1155/2014/890230] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 2.3] [Reference Citation Analysis]
14 Moesinger RC, Davis JW, Hill B, Johnston WC, Gray C, Johnson H, Ingersoll L, Whipple G, Reilly M, Harris R, Hansen V. Treatment of pancreatic and periampullary cancers at a community hospital: successful application of tertiary care treatment standards. Int J Surg Oncol 2011;2011:936516. [PMID: 22312532 DOI: 10.1155/2011/936516] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
15 Beyer G, Hoffmeister A, Michl P, Gress TM, Huber W, Algül H, Neesse A, Meining A, Seufferlein TW, Rosendahl J, Kahl S, Keller J, Werner J, Friess H, Bufler P, Löhr MJ, Schneider A, Lynen Jansen P, Esposito I, Grenacher L, Mössner J, Lerch MM, Mayerle J; Collaborators:. S3-Leitlinie Pankreatitis – Leitlinie der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) – September 2021 – AWMF Registernummer 021-003. Z Gastroenterol 2022;60:419-521. [PMID: 35263785 DOI: 10.1055/a-1735-3864] [Reference Citation Analysis]
16 Ren X, Wei X, Ding Y, Qi F, Zhang Y, Hu X, Qin C, Li X. Comparison of neoadjuvant therapy and upfront surgery in resectable pancreatic cancer: a meta-analysis and systematic review. Onco Targets Ther 2019;12:733-44. [PMID: 30774360 DOI: 10.2147/OTT.S190810] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
17 Vincent A, Herman J, Schulick R, Hruban RH, Goggins M. Pancreatic cancer. Lancet. 2011;378:607-620. [PMID: 21620466 DOI: 10.1016/so140-6736(10)62307-0] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
18 Irfan A, Fang HA, Awad S, Alkashah A, Vickers SM, Gbolahan O, Williams GR, Nien-tsu Wang T, Dudeja V, Rose JB, Reddy S. Does race affect the long-term survival benefit of systemic therapy in pancreatic adenocarcinoma? The American Journal of Surgery 2022. [DOI: 10.1016/j.amjsurg.2022.04.004] [Reference Citation Analysis]
19 Osei E, Francis R, Mohamed A, Sheraz L, Soltani-mayvan F. Impact of COVID-19 pandemic on the oncologic care continuum: urgent need to restore patients care to pre-COVID-19 era. J Radiother Pract. [DOI: 10.1017/s1460396921000303] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
20 Li D, Xie K, Wolff R, Abbruzzese JL. Pancreatic cancer. The Lancet 2004;363:1049-57. [DOI: 10.1016/s0140-6736(04)15841-8] [Cited by in Crossref: 1360] [Cited by in F6Publishing: 672] [Article Influence: 75.6] [Reference Citation Analysis]
21 Thomas AS, Sharma RK, Kwon W, Sugahara KN, Chabot JA, Schrope BA, Kluger MD. Socioeconomic Predictors of Access to Care for Patients with Operatively Managed Pancreatic Cancer in New York State. J Gastrointest Surg. [DOI: 10.1007/s11605-022-05320-1] [Reference Citation Analysis]
22 Krantz SB, Bentrem DJ. It takes a village: defining the value of dedicated multidisciplinary teams in cancer outcomes. J Surg Res 2012;173:51-3. [PMID: 21435654 DOI: 10.1016/j.jss.2011.01.020] [Reference Citation Analysis]
23 Poruk KE, Valero V 3rd, Saunders T, Blackford AL, Griffin JF, Poling J, Hruban RH, Anders RA, Herman J, Zheng L, Rasheed ZA, Laheru DA, Ahuja N, Weiss MJ, Cameron JL, Goggins M, Iacobuzio-Donahue CA, Wood LD, Wolfgang CL. Circulating Tumor Cell Phenotype Predicts Recurrence and Survival in Pancreatic Adenocarcinoma. Ann Surg 2016;264:1073-81. [PMID: 26756760 DOI: 10.1097/SLA.0000000000001600] [Cited by in Crossref: 73] [Cited by in F6Publishing: 50] [Article Influence: 14.6] [Reference Citation Analysis]
24 Hurwitz HI, Uppal N, Wagner SA, Bendell JC, Beck JT, Wade SM 3rd, Nemunaitis JJ, Stella PJ, Pipas JM, Wainberg ZA, Manges R, Garrett WM, Hunter DS, Clark J, Leopold L, Sandor V, Levy RS. Randomized, Double-Blind, Phase II Study of Ruxolitinib or Placebo in Combination With Capecitabine in Patients With Metastatic Pancreatic Cancer for Whom Therapy With Gemcitabine Has Failed. J Clin Oncol. 2015;33:4039-4047. [PMID: 26351344 DOI: 10.1200/jco.2015.61.4578] [Cited by in Crossref: 155] [Cited by in F6Publishing: 90] [Article Influence: 22.1] [Reference Citation Analysis]
25 Nie D, Lai G, An G, Wu Z, Lei S, Li J, Cao J. Individualized Prediction of Survival Benefits of Pancreatectomy Plus Chemotherapy in Patients With Simultaneous Metastatic Pancreatic Cancer. Front Oncol 2021;11:719253. [PMID: 34604055 DOI: 10.3389/fonc.2021.719253] [Reference Citation Analysis]
26 Onete VG, Besselink MG, Salsbach CM, Van Eijck CH, Busch OR, Gouma DJ, de Hingh IH, Sieders E, Dejong CH, Offerhaus JG, Molenaar IQ; Dutch Pancreatic Cancer Group. Impact of centralization of pancreatoduodenectomy on reported radical resections rates in a nationwide pathology database. HPB (Oxford) 2015;17:736-42. [PMID: 26037776 DOI: 10.1111/hpb.12425] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 3.1] [Reference Citation Analysis]
27 Lahat G, Sever R, Lubezky N, Nachmany I, Gerstenhaber F, Ben-Haim M, Nakache R, Koriansky J, Klausner JM. Pancreatic cancer: surgery is a feasible therapeutic option for elderly patients. World J Surg Oncol. 2011;9:10. [PMID: 21272335 DOI: 10.1186/1477-7819-9-10] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 2.2] [Reference Citation Analysis]
28 Ransome E, Tong L, Espinosa J, Chou J, Somnay V, Munene G. Trends in surgery and disparities in receipt of surgery for intrahepatic cholangiocarcinoma in the US: 2005-2014. J Gastrointest Oncol 2019;10:339-47. [PMID: 31032103 DOI: 10.21037/jgo.2018.12.07] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
29 Wachtel MS, Xu KT, Zhang Y, Chiriva-Internati M, Frezza EE. Pancreas cancer survival in the gemcitabine era. Clin Med Oncol 2008;2:405-13. [PMID: 21892307 DOI: 10.4137/cmo.s334] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
30 Herreros-Villanueva M, Hijona E, Cosme A, Bujanda L. Adjuvant and neoadjuvant treatment in pancreatic cancer. World J Gastroenterol 2012; 18(14): 1565-1572 [PMID: 22529684 DOI: 10.3748/wjg.v18.i14.1565] [Cited by in CrossRef: 36] [Cited by in F6Publishing: 34] [Article Influence: 3.6] [Reference Citation Analysis]
31 Revels SL, Morris AM, Reddy RM, Akateh C, Wong SL. Racial disparities in esophageal cancer outcomes. Ann Surg Oncol. 2013;20:1136-1141. [PMID: 23263780 DOI: 10.1245/s10434-012-2807-3] [Cited by in Crossref: 41] [Cited by in F6Publishing: 44] [Article Influence: 4.1] [Reference Citation Analysis]
32 van der Geest LGM, van Eijck CHJ, Groot Koerkamp B, Lemmens VEPP, Busch OR, Vissers PAJ, Wilmink JW, Besselink MG; Dutch Pancreatic Cancer Group. Trends in treatment and survival of patients with nonresected, nonmetastatic pancreatic cancer: A population-based study. Cancer Med 2018;7:4943-51. [PMID: 30188015 DOI: 10.1002/cam4.1750] [Cited by in Crossref: 9] [Cited by in F6Publishing: 13] [Article Influence: 2.3] [Reference Citation Analysis]
33 Lewis R, Drebin JA, Callery MP, Fraker D, Kent TS, Gates J, Vollmer CM. A contemporary analysis of survival for resected pancreatic ductal adenocarcinoma. HPB (Oxford). 2013;15:49-60. [PMID: 23216779 DOI: 10.1111/j.1477-2574.2012.00571.x] [Cited by in Crossref: 72] [Cited by in F6Publishing: 69] [Article Influence: 7.2] [Reference Citation Analysis]
34 Showalter SL, Huang YH, Witkiewicz A, Costantino CL, Yeo CJ, Green JJ, Langer R, Anderson DG, Sawicki JA, Brody JR. Nanoparticulate delivery of diphtheria toxin DNA effectively kills Mesothelin expressing pancreatic cancer cells. Cancer Biol Ther. 2008;7:1584-1590. [PMID: 19039293 DOI: 10.4161/cbt.7.10.6562] [Cited by in Crossref: 40] [Cited by in F6Publishing: 35] [Article Influence: 2.9] [Reference Citation Analysis]
35 Martín AJ, Alfonso PG, Rupérez AB, Jiménez MM. Nab-paclitaxel plus gemcitabine as first-line palliative chemotherapy in a patient with metastatic pancreatic cancer with Eastern Cooperative Oncology Group performance status of 2. Oncol Lett 2016;12:727-30. [PMID: 27347207 DOI: 10.3892/ol.2016.4667] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
36 Mao Y, Xi L, Li Q, Cai Z, Lai Y, Zhang X, Yu C. Regulation of cell apoptosis and proliferation in pancreatic cancer through PI3K/Akt pathway via Polo-like kinase 1. Oncol Rep. 2016;36:49-56. [PMID: 27220401 DOI: 10.3892/or.2016.4820] [Cited by in Crossref: 37] [Cited by in F6Publishing: 36] [Article Influence: 6.2] [Reference Citation Analysis]
37 Kakoza RM, Vollmer CM Jr, Stuart KE, Takoudes T, Hanto DW. Pancreatic adenocarcinoma in the pregnant patient: a case report and literature review. J Gastrointest Surg 2009;13:535-41. [PMID: 18815844 DOI: 10.1007/s11605-008-0697-2] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
38 Pilli VS, Datta A, Dorsey A, Liu B, Majumder R. Modulation of protein S and growth arrest specific 6 protein signaling inhibits pancreatic cancer cell survival and proliferation. Oncol Rep 2020;44:1322-32. [PMID: 32945517 DOI: 10.3892/or.2020.7689] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
39 Kumar D, Dey T. Treatment delays in oncology patients during COVID-19 pandemic: A perspective. J Glob Health 2020;10:010367. [PMID: 32566158 DOI: 10.7189/jogh.10.010367] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 9.0] [Reference Citation Analysis]
40 Chandrabalan VV, McMillan DC, Carter R, Kinsella J, McKay CJ, Carter CR, Dickson EJ. Pre-operative cardiopulmonary exercise testing predicts adverse post-operative events and non-progression to adjuvant therapy after major pancreatic surgery. HPB (Oxford) 2013;15:899-907. [PMID: 23458160 DOI: 10.1111/hpb.12060] [Cited by in Crossref: 32] [Cited by in F6Publishing: 28] [Article Influence: 3.6] [Reference Citation Analysis]
41 Ellis RJ, Ho JW, Schlick CJR, Merkow RP, Bentrem DJ, Bilimoria KY, Yang AD. National Use of Chemotherapy in Initial Management of Stage I Pancreatic Cancer and Failure to Perform Subsequent Resection. Ann Surg Oncol. 2020;27:909-918. [PMID: 31691112 DOI: 10.1245/s10434-019-08023-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
42 Joshi KS, Bodepudi S, Ganapathi SK, Murugesan C, Balu J, Subramanian S. Pancreatic malignancy in the backdrop of chronic pancreatitis: How much to push the boundaries to achieve R0 resection. Forum of Clinical Oncology 2021;12:47-51. [DOI: 10.2478/fco-2019-0011] [Reference Citation Analysis]
43 Sánchez-Bueno F, García-Pérez R, Claver Valderas MA, de la Peña Moral J, Frutos Esteban L, Ortiz Ruiz E, Fuster Quiñonero M, Parrilla Paricio P. Utility of 18 fludeoxyglucose in preoperative positon-emission tomography-computed tomography (PET-CT) in the early diagnosis of exocrine pancreatic cancer: A study of 139 resected cases. Cir Esp 2016;94:511-7. [PMID: 27712835 DOI: 10.1016/j.ciresp.2016.07.007] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
44 Vincent A, Herman J, Schulick R, Hruban RH, Goggins M. Pancreatic cancer. Lancet. 2011;378:607-620. [PMID: 21620466 DOI: 10.1016/s0140-6736(10)62307-0] [Cited by in Crossref: 1377] [Cited by in F6Publishing: 849] [Article Influence: 125.2] [Reference Citation Analysis]
45 Kent TS, Sachs TE, Sanchez N, Vollmer CM Jr, Callery MP. Conditional survival in pancreatic cancer: better than expected. HPB (Oxford) 2011;13:876-80. [PMID: 22081923 DOI: 10.1111/j.1477-2574.2011.00379.x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.2] [Reference Citation Analysis]
46 Mitchell RA, Stanger D, Shuster C, Telford J, Lam E, Enns R. Repeat Endoscopic Ultrasound-Guided Fine-Needle Aspiration in Patients with Suspected Pancreatic Cancer: Diagnostic Yield and Associated Change in Access to Appropriate Care. Can J Gastroenterol Hepatol 2016;2016:7678403. [PMID: 27648440 DOI: 10.1155/2016/7678403] [Cited by in Crossref: 1] [Cited by in F6Publishing: 6] [Article Influence: 0.2] [Reference Citation Analysis]
47 Looijen GA, Pranger BK, de Jong KP, Pennings JP, de Meijer VE, Erdmann JI. The Additional Value of Laparoscopic Ultrasound to Staging Laparoscopy in Patients with Suspected Pancreatic Head Cancer. J Gastrointest Surg 2018;22:1186-92. [PMID: 29532360 DOI: 10.1007/s11605-018-3726-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
48 Ratnayake B, Al-Leswas D, Mohammadi-Zaniani G, Littler P, Sen G, Manas D, Pandanaboyana S. Margin Accentuation Irreversible Electroporation in Stage III Pancreatic Cancer: A Systematic Review. Cancers (Basel) 2021;13:3212. [PMID: 34199031 DOI: 10.3390/cancers13133212] [Reference Citation Analysis]
49 Shaib WL, Zakka K, Shahin AA, Yared F, Switchenko JM, Wu C, Akce M, Alese OB, Patel PR, Mcdonald M, El-Rayes BF. Radiation as a Single-Modality Treatment in Localized Pancreatic Cancer. Pancreas 2020;49:822-9. [PMID: 32541638 DOI: 10.1097/MPA.0000000000001584] [Reference Citation Analysis]
50 Aldakkak M, Christians KK, Krepline AN, George B, Ritch PS, Erickson BA, Johnston FM, Evans DB, Tsai S. Pre-treatment carbohydrate antigen 19-9 does not predict the response to neoadjuvant therapy in patients with localized pancreatic cancer. HPB (Oxford) 2015;17:942-52. [PMID: 26255895 DOI: 10.1111/hpb.12448] [Cited by in Crossref: 35] [Cited by in F6Publishing: 24] [Article Influence: 5.0] [Reference Citation Analysis]
51 Riall TS, Townsend CM, Kuo YF, Freeman JL, Goodwin JS. Dissecting racial disparities in the treatment of patients with locoregional pancreatic cancer: a 2-step process. Cancer. 2010;116:930-939. [PMID: 20052726 DOI: 10.1002/cncr.24836] [Cited by in Crossref: 52] [Cited by in F6Publishing: 52] [Article Influence: 4.3] [Reference Citation Analysis]
52 Gold DV, Goggins M, Modrak DE, Newsome G, Liu M, Shi C, Hruban RH, Goldenberg DM. Detection of early-stage pancreatic adenocarcinoma. Cancer Epidemiol Biomarkers Prev. 2010;19:2786-2794. [PMID: 20810605 DOI: 10.1158/1055-9965.epi-10-0667] [Cited by in Crossref: 36] [Cited by in F6Publishing: 30] [Article Influence: 3.0] [Reference Citation Analysis]
53 Frappart PO, Hofmann TG. Pancreatic Ductal Adenocarcinoma (PDAC) Organoids: The Shining Light at the End of the Tunnel for Drug Response Prediction and Personalized Medicine. Cancers (Basel) 2020;12:E2750. [PMID: 32987786 DOI: 10.3390/cancers12102750] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 5.5] [Reference Citation Analysis]
54 Wei AC, Devitt KS, Wiebe M, Bathe OF, McLeod RS, Urbach DR. Surgical process improvement tools: defining quality gaps and priority areas in gastrointestinal cancer surgery. Curr Oncol 2014;21:e195-202. [PMID: 24764704 DOI: 10.3747/co.21.1733] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
55 Dubecz A, Solymosi N, Schweigert M, Stadlhuber RJ, Peters JH, Ofner D, Stein HJ. Time trends and disparities in lymphadenectomy for gastrointestinal cancer in the United States: a population-based analysis of 326,243 patients. J Gastrointest Surg. 2013;17:611-618; discussion 618-619. [PMID: 23340992 DOI: 10.1007/s11605-013-2146-0] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 2.0] [Reference Citation Analysis]
56 Loehrer AP, Chang DC, Hutter MM, Song Z, Lillemoe KD, Warshaw AL, Ferrone CR. Health Insurance Expansion and Treatment of Pancreatic Cancer: Does Increased Access Lead to Improved Care? J Am Coll Surg 2015;221:1015-22. [PMID: 26611798 DOI: 10.1016/j.jamcollsurg.2015.09.010] [Cited by in Crossref: 28] [Cited by in F6Publishing: 31] [Article Influence: 4.0] [Reference Citation Analysis]
57 Parray A, Bhandare MS, Pandrowala S, Chaudhari VA, Shrikhande SV. Peri-operative, long-term, and quality of life outcomes after pancreaticoduodenectomy in the elderly: greater justification for periampullary cancer compared to pancreatic head cancer. HPB (Oxford) 2021;23:777-84. [PMID: 33041206 DOI: 10.1016/j.hpb.2020.09.016] [Reference Citation Analysis]
58 Torres MB, Dixon MEB, Gusani NJ. Undertreatment of Pancreatic Cancer: The Intersection of Bias, Biology, and Geography. Surg Oncol Clin N Am 2022;31:43-54. [PMID: 34776063 DOI: 10.1016/j.soc.2021.07.006] [Reference Citation Analysis]
59 Underwood PW, Trevino JG. A deeper understanding of the tumor microenvironment in pancreatic cancer: the key to developing effective immunotherapies. Ann Transl Med 2019;7:162. [PMID: 31168443 DOI: 10.21037/atm.2019.03.14] [Reference Citation Analysis]
60 Zavala VA, Bracci PM, Carethers JM, Carvajal-Carmona L, Coggins NB, Cruz-Correa MR, Davis M, de Smith AJ, Dutil J, Figueiredo JC, Fox R, Graves KD, Gomez SL, Llera A, Neuhausen SL, Newman L, Nguyen T, Palmer JR, Palmer NR, Pérez-Stable EJ, Piawah S, Rodriquez EJ, Sanabria-Salas MC, Schmit SL, Serrano-Gomez SJ, Stern MC, Weitzel J, Yang JJ, Zabaleta J, Ziv E, Fejerman L. Cancer health disparities in racial/ethnic minorities in the United States. Br J Cancer 2021;124:315-32. [PMID: 32901135 DOI: 10.1038/s41416-020-01038-6] [Cited by in Crossref: 48] [Cited by in F6Publishing: 47] [Article Influence: 24.0] [Reference Citation Analysis]
61 Fonseca AL, Khan H, Mehari KR, Cherla D, Heslin MJ, Johnston FM. Disparities in Access to Oncologic Care in Pancreatic Cancer: A Systematic Review. Ann Surg Oncol. [DOI: 10.1245/s10434-021-11258-6] [Reference Citation Analysis]
62 Shohat S, Shulman K, Kessel B, Gal O, Zeina AR. Spontaneous Rupture of the Main Pancreatic Duct Synchronous With a Multi-Focal Microscopic Pancreatic Adenocarcinoma: A Case Report. J Clin Diagn Res 2016;10:PD15-7. [PMID: 28208932 DOI: 10.7860/JCDR/2016/21767.9086] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
63 Eskander MF, Hamad A, Li Y, Fisher JL, Oppong B, Obeng-Gyasi S, Tsung A. From street address to survival: Neighborhood socioeconomic status and pancreatic cancer outcomes. Surgery 2021:S0039-6060(21)00992-2. [PMID: 34876291 DOI: 10.1016/j.surg.2021.10.027] [Reference Citation Analysis]
64 Wegner RE, Verma V, Hasan S, Schiffman S, Thakkar S, Horne ZD, Kulkarni A, Williams HK, Monga D, Finley G, Kirichenko AV. Incidence and risk factors for post-operative mortality, hospitalization, and readmission rates following pancreatic cancer resection. J Gastrointest Oncol. 2019;10:1080-1093. [PMID: 31949925 DOI: 10.21037/jgo.2019.09.01] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
65 Pan C, Yang KX. Long noncoding RNAs in pancreatic cancer. Shijie Huaren Xiaohua Zazhi 2015; 23(4): 563-569 [DOI: 10.11569/wcjd.v23.i4.563] [Reference Citation Analysis]
66 Vanderveen KA, Chen SL, Yin D, Cress RD, Bold RJ. Benefit of postoperative adjuvant therapy for pancreatic cancer: A population-based analysis. Cancer. 2009;115:2420-2429. [PMID: 19301434 DOI: 10.1002/cncr.24269] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 0.8] [Reference Citation Analysis]
67 Liang C, Xu J, Meng Q, Zhang B, Liu J, Hua J, Zhang Y, Shi S, Yu X. TGFB1-induced autophagy affects the pattern of pancreatic cancer progression in distinct ways depending on SMAD4 status. Autophagy 2020;16:486-500. [PMID: 31177911 DOI: 10.1080/15548627.2019.1628540] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 5.3] [Reference Citation Analysis]
68 Enewold L, Harlan LC, Tucker T, McKenzie S. Pancreatic cancer in the USA: persistence of undertreatment and poor outcome. J Gastrointest Cancer 2015;46:9-20. [PMID: 25403828 DOI: 10.1007/s12029-014-9668-x] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 3.9] [Reference Citation Analysis]
69 Gabriel E, Thirunavukarasu P, Attwood K, Nurkin SJ. National disparities in minimally invasive surgery for pancreatic tumors. Surg Endosc 2017;31:398-409. [PMID: 27412124 DOI: 10.1007/s00464-016-4987-6] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
70 Kawaguchi T, Komatsu S, Ichikawa D, Morimura R, Tsujiura M, Konishi H, Takeshita H, Nagata H, Arita T, Hirajima S. Clinical impact of circulating miR-221 in plasma of patients with pancreatic cancer. Br J Cancer. 2013;108:361-369. [PMID: 23329235 DOI: 10.1038/bjc.2012.546] [Cited by in Crossref: 137] [Cited by in F6Publishing: 142] [Article Influence: 15.2] [Reference Citation Analysis]
71 Bieg C, Mongelli F, Peterli R, Chirindel AF, Metzger J, von Flüe M, Gass M. Simplified dual time point FDG-PET/computed tomography for determining dignity of pancreatic lesions. Nucl Med Commun 2020;41:682-7. [PMID: 32404649 DOI: 10.1097/MNM.0000000000001191] [Reference Citation Analysis]
72 Zhang K, Lu Z, Zhu Y, Tian L, Zhang J, Xi C, Gao W, Jiang K, Miao Y. The clinical value, regulatory mechanisms, and gene network of the cancer-testis gene STK31 in pancreatic cancer. Oncotarget 2017;8:35154-64. [PMID: 28422722 DOI: 10.18632/oncotarget.16814] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
73 Storino A, Guetter C, Castillo-Angeles M, Watkins AA, Mancias JD, Bullock A, James Moser A, Kent TS. What Patients Look for When Browsing Online for Pancreatic Cancer: The Bait Behind the Byte. World J Surg 2018;42:4097-106. [PMID: 29971463 DOI: 10.1007/s00268-018-4719-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
74 Torres MP, Rachagani S, Purohit V, Pandey P, Joshi S, Moore ED, Johansson SL, Singh PK, Ganti AK, Batra SK. Graviola: a novel promising natural-derived drug that inhibits tumorigenicity and metastasis of pancreatic cancer cells in vitro and in vivo through altering cell metabolism. Cancer Lett. 2012;323:29-40. [PMID: 22475682 DOI: 10.1016/j.canlet.2012.03.031] [Cited by in Crossref: 85] [Cited by in F6Publishing: 76] [Article Influence: 8.5] [Reference Citation Analysis]
75 Fong ZV, Tan WP, Lavu H, Kennedy EP, Mitchell DG, Koniaris LG, Sauter PK, Rosato EL, Yeo CJ, Winter JM. Preoperative imaging for resectable periampullary cancer: clinicopathologic implications of reported radiographic findings. J Gastrointest Surg 2013;17:1098-106. [PMID: 23553385 DOI: 10.1007/s11605-013-2181-x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 1.9] [Reference Citation Analysis]
76 Tempero MA, Arnoletti JP, Behrman S, Ben-Josef E, Benson AB 3rd, Berlin JD, Cameron JL, Casper ES, Cohen SJ, Duff M, Ellenhorn JD, Hawkins WG, Hoffman JP, Kuvshinoff BW 2nd, Malafa MP, Muscarella P 2nd, Nakakura EK, Sasson AR, Thayer SP, Tyler DS, Warren RS, Whiting S, Willett C, Wolff RA; NCCN Pancreatic Adenocarcinoma. Pancreatic adenocarcinoma. J Natl Compr Canc Netw 2010;8:972-1017. [PMID: 20876541 DOI: 10.6004/jnccn.2010.0073] [Cited by in Crossref: 122] [Cited by in F6Publishing: 111] [Article Influence: 10.2] [Reference Citation Analysis]
77 Michalski CW, Liu B, Heckler M, Roth S, Sun H, Heger U, Büchler MW, Hackert T. Underutilization of Surgery in Periampullary Cancer Treatment. J Gastrointest Surg 2019;23:959-65. [PMID: 30088190 DOI: 10.1007/s11605-018-3897-4] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
78 Franko J, Krasinskas AM, Nikiforova MN, Zarnescu NO, Lee KK, Hughes SJ, Bartlett DL, Zeh HJ, Moser AJ. Loss of heterozygosity predicts poor survival after resection of pancreatic adenocarcinoma. J Gastrointest Surg. 2008;12:1664-1672; discussion 1672-1673. [PMID: 18677542 DOI: 10.1007/s11605-008-0577-9] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 1.4] [Reference Citation Analysis]
79 Mena E, Sheikhbahaei S, Taghipour M, Jha AK, Vicente E, Xiao J, Subramaniam RM. 18F-FDG PET/CT Metabolic Tumor Volume and Intratumoral Heterogeneity in Pancreatic Adenocarcinomas: Impact of Dual-Time Point and Segmentation Methods. Clin Nucl Med 2017;42:e16-21. [PMID: 27819858 DOI: 10.1097/RLU.0000000000001446] [Cited by in Crossref: 14] [Cited by in F6Publishing: 5] [Article Influence: 2.8] [Reference Citation Analysis]
80 Nordby T, Ikdahl T, Lothe IM, Ånonsen K, Hauge T, Edwin B, Line PD, Labori KJ, Buanes T. Opportunities of improvement in the management of pancreatic and periampullary tumors. Scand J Gastroenterol 2013;48:617-25. [PMID: 23597153 DOI: 10.3109/00365521.2013.781218] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
81 Kim SH, Chong JU, Lim JH, Chung MJ, Park JY, Bang SM, Park SW, Hwang HK, Kang CM, Lee WJ, Kim KS. Oncologic outcomes after radical surgery for periampullary cancer in octogenarians. Ann Hepatobiliary Pancreat Surg 2018;22:128-35. [PMID: 29896573 DOI: 10.14701/ahbps.2018.22.2.128] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
82 Birnbaum DJ, Bertucci F, Finetti P, Birnbaum D, Mamessier E. Head and Body/Tail Pancreatic Carcinomas Are Not the Same Tumors. Cancers (Basel). 2019;11. [PMID: 30965637 DOI: 10.3390/cancers11040497] [Cited by in Crossref: 29] [Cited by in F6Publishing: 31] [Article Influence: 9.7] [Reference Citation Analysis]
83 Qiao Z, He M, He MU, Li W, Wang X, Wang Y, Kuai Q, Li C, Ren S, Yu Q. Synergistic antitumor activity of gemcitabine combined with triptolide in pancreatic cancer cells. Oncol Lett. 2016;11:3527-3533. [PMID: 27123146 DOI: 10.3892/ol.2016.4379] [Cited by in Crossref: 13] [Cited by in F6Publishing: 16] [Article Influence: 2.2] [Reference Citation Analysis]
84 Arnaoutakis GJ, Rangachari D, Laheru DA, Iacobuzio-Donahue CA, Hruban RH, Herman JM, Edil BH, Pawlik TM, Schulick RD, Cameron JL. Pulmonary resection for isolated pancreatic adenocarcinoma metastasis: an analysis of outcomes and survival. J Gastrointest Surg. 2011;15:1611-1617. [PMID: 21725701 DOI: 10.1007/s11605-011-1605-8] [Cited by in Crossref: 85] [Cited by in F6Publishing: 71] [Article Influence: 7.7] [Reference Citation Analysis]
85 Motoi F, Satoi S, Honda G, Wada K, Shinchi H, Matsumoto I, Sho M, Tsuchida A, Unno M; Study Group of Preoperative therapy for Pancreatic cancer (PREP). A single-arm, phase II trial of neoadjuvant gemcitabine and S1 in patients with resectable and borderline resectable pancreatic adenocarcinoma: PREP-01 study. J Gastroenterol 2019;54:194-203. [PMID: 30182219 DOI: 10.1007/s00535-018-1506-7] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 6.5] [Reference Citation Analysis]
86 Kamarajah SK, Nathan H. Strengths and Limitations of Registries in Surgical Oncology Research. J Gastrointest Surg 2021. [PMID: 34506025 DOI: 10.1007/s11605-021-05094-y] [Reference Citation Analysis]
87 Royal RE, Levy C, Turner K, Mathur A, Hughes M, Kammula US, Sherry RM, Topalian SL, Yang JC, Lowy I, Rosenberg SA. Phase 2 trial of single agent Ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma. J Immunother. 2010;33:828-833. [PMID: 20842054 DOI: 10.1097/cji.0b013eec14c] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
88 Wakiya T, Ishido K, Kimura N, Nagase H, Kubota S, Fujita H, Hagiwara Y, Kanda T, Matsuzaka M, Sasaki Y, Hakamada K. Prediction of massive bleeding in pancreatic surgery based on preoperative patient characteristics using a decision tree. PLoS One 2021;16:e0259682. [PMID: 34752505 DOI: 10.1371/journal.pone.0259682] [Reference Citation Analysis]
89 Khalaf N, Yuan C, Hamada T, Cao Y, Babic A, Morales-Oyarvide V, Kraft P, Ng K, Giovannucci E, Ogino S, Stampfer M, Cochrane BB, Manson JE, Clish CB, Chan AT, Fuchs CS, Wolpin BM. Regular Use of Aspirin or Non-Aspirin Nonsteroidal Anti-Inflammatory Drugs Is Not Associated With Risk of Incident Pancreatic Cancer in Two Large Cohort Studies. Gastroenterology 2018;154:1380-1390.e5. [PMID: 29229401 DOI: 10.1053/j.gastro.2017.12.001] [Cited by in Crossref: 30] [Cited by in F6Publishing: 22] [Article Influence: 6.0] [Reference Citation Analysis]
90 Kim KS, Kwon J, Kim K, Chie EK. Impact of Resection Margin Distance on Survival of Pancreatic Cancer: A Systematic Review and Meta-Analysis. Cancer Res Treat. 2017;49:824-833. [PMID: 27561314 DOI: 10.4143/crt.2016.336] [Cited by in Crossref: 44] [Cited by in F6Publishing: 40] [Article Influence: 7.3] [Reference Citation Analysis]
91 Lowy AM. Beyond the ivory tower: outcomes following surgery for ampullary cancer. Ann Surg Oncol 2008;15:1813-4. [PMID: 18425553 DOI: 10.1245/s10434-008-9918-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
92 de Rooij T, Klompmaker S, Abu Hilal M, Kendrick ML, Busch OR, Besselink MG. Laparoscopic pancreatic surgery for benign and malignant disease. Nat Rev Gastroenterol Hepatol. 2016;13:227-238. [PMID: 26882881 DOI: 10.1038/nrgastro.2016.17] [Cited by in Crossref: 73] [Cited by in F6Publishing: 57] [Article Influence: 12.2] [Reference Citation Analysis]
93 Aarnink A, Richard C, Truntzer C, Vincent J, Bengrine L, Vienot A, Borg C, Ghiringhelli F. Baseline splenic volume as a surrogate marker of FOLFIRINOX efficacy in advanced pancreatic carcinoma. Oncotarget 2018;9:25617-29. [PMID: 29876012 DOI: 10.18632/oncotarget.25424] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
94 Kim-Fuchs C, Le CP, Pimentel MA, Shackleford D, Ferrari D, Angst E, Hollande F, Sloan EK. Chronic stress accelerates pancreatic cancer growth and invasion: a critical role for beta-adrenergic signaling in the pancreatic microenvironment. Brain Behav Immun 2014;40:40-7. [PMID: 24650449 DOI: 10.1016/j.bbi.2014.02.019] [Cited by in Crossref: 106] [Cited by in F6Publishing: 107] [Article Influence: 13.3] [Reference Citation Analysis]
95 Sakin A, Sahin S, Mustafa atci M, Demir C, Yasar N, Geredeli C, Cihan S. The evaluation of efficacy and tolerability of gemcitabine vs. capecitabine therapy in the second-line setting for metastatic pancreatic cancer patients with poor performance status. Journal of Oncological Sciences 2019;5:85-9. [DOI: 10.1016/j.jons.2019.08.003] [Reference Citation Analysis]
96 Bilimoria KY, Tomlinson JS, Merkow RP, Stewart AK, Ko CY, Talamonti MS, Bentrem DJ. Clinicopathologic features and treatment trends of pancreatic neuroendocrine tumors: analysis of 9,821 patients. J Gastrointest Surg. 2007;11:1460-1467; discussion 1467-1469. [PMID: 17846854 DOI: 10.1007/s11605-007-0263-3] [Cited by in Crossref: 111] [Cited by in F6Publishing: 102] [Article Influence: 7.4] [Reference Citation Analysis]
97 Sharma C, Eltawil KM, Renfrew PD, Walsh MJ, Molinari M. Advances in diagnosis, treatment and palliation of pancreatic carcinoma: 1990-2010. World J Gastroenterol 2011; 17(7): 867-897 [PMID: 21412497 DOI: 10.3748/wjg.v17.i7.867] [Cited by in CrossRef: 119] [Cited by in F6Publishing: 109] [Article Influence: 10.8] [Reference Citation Analysis]
98 Franko J, Frankova D. Effect of Surgical Oncologist Turnover on Hospital Volume and Treatment Outcomes Among Patients With Upper GI Malignancies. JCO Oncol Pract 2020;16:e1161-8. [PMID: 32539648 DOI: 10.1200/JOP.19.00761] [Reference Citation Analysis]
99 Creighton N, Walton R, Roder D, Aranda S, Currow D. Validation of administrative hospital data for identifying incident pancreatic and periampullary cancer cases: a population-based study using linked cancer registry and administrative hospital data in New South Wales, Australia. BMJ Open 2016;6:e011161. [PMID: 27371553 DOI: 10.1136/bmjopen-2016-011161] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
100 Borgida AE, Ashamalla S, Al-Sukhni W, Rothenmund H, Urbach D, Moore M, Cotterchio M, Gallinger S. Management of pancreatic adenocarcinoma in Ontario, Canada: a population-based study using novel case ascertainment. Can J Surg 2011;54:54-60. [PMID: 21251433 DOI: 10.1503/cjs.026409] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
101 Molina G, Clancy TE, Tsai TC, Lam M, Wang J. Racial Disparity in Pancreatoduodenectomy for Borderline Resectable Pancreatic Adenocarcinoma. Ann Surg Oncol 2021;28:1088-96. [PMID: 32651695 DOI: 10.1245/s10434-020-08717-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
102 Boyd CA, Branch DW, Sheffield KM, Han Y, Kuo YF, Goodwin JS, Riall TS. Hospital and medical care days in pancreatic cancer. Ann Surg Oncol 2012;19:2435-42. [PMID: 22451235 DOI: 10.1245/s10434-012-2326-2] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
103 Swords DS, Firpo MA, Johnson KM, Boucher KM, Scaife CL, Mulvihill SJ. Implications of inaccurate clinical nodal staging in pancreatic adenocarcinoma. Surgery 2017;162:104-11. [PMID: 28238344 DOI: 10.1016/j.surg.2016.12.029] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
104 Melo SA, Luecke LB, Kahlert C, Fernandez AF, Gammon ST, Kaye J, LeBleu VS, Mittendorf EA, Weitz J, Rahbari N, Reissfelder C, Pilarsky C, Fraga MF, Piwnica-Worms D, Kalluri R. Glypican-1 identifies cancer exosomes and detects early pancreatic cancer. Nature. 2015;523:177-182. [PMID: 26106858 DOI: 10.1038/nature14581] [Cited by in Crossref: 1361] [Cited by in F6Publishing: 1346] [Article Influence: 194.4] [Reference Citation Analysis]
105 Zheng Z, Tan C, Chen Y, Ping J, Wang M. Impact of different surgical procedures on survival outcomes of patients with adenocarcinoma of pancreatic neck. PLoS One 2019;14:e0217427. [PMID: 31125386 DOI: 10.1371/journal.pone.0217427] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
106 Fong ZV, Loehrer AP, Fernández-Del Castillo C, Bababekov YJ, Jin G, Ferrone CR, Warshaw AL, Traeger LN, Hutter MM, Lillemoe KD, Chang DC. Potential impact of a volume pledge on spatial access: A population-level analysis of patients undergoing pancreatectomy. Surgery 2017;162:203-10. [PMID: 28504112 DOI: 10.1016/j.surg.2017.03.010] [Cited by in Crossref: 27] [Cited by in F6Publishing: 21] [Article Influence: 5.4] [Reference Citation Analysis]
107 Bilimoria KY, Bentrem DJ, Lillemoe KD, Talamonti MS, Ko CY;  Pancreatic Cancer Quality Indicator Development Expert Panel; American College of Surgeons. Assessment of pancreatic cancer care in the United States based on formally developed quality indicators. J Natl Cancer Inst. 2009;101:848-859. [PMID: 19509366 DOI: 10.1093/jnci/djp107] [Cited by in Crossref: 85] [Cited by in F6Publishing: 78] [Article Influence: 6.5] [Reference Citation Analysis]
108 Parmar AD, Vargas GM, Tamirisa NP, Sheffield KM, Riall TS. Trajectory of care and use of multimodality therapy in older patients with pancreatic adenocarcinoma. Surgery. 2014;156:280-289. [PMID: 24851723 DOI: 10.1016/j.surg.2014.03.001] [Cited by in Crossref: 49] [Cited by in F6Publishing: 37] [Article Influence: 6.1] [Reference Citation Analysis]
109 Khanal N, Upadhyay S, Dahal S, Bhatt VR, Silberstein PT. Systemic therapy in stage IV pancreatic cancer: a population-based analysis using the National Cancer Data Base. Ther Adv Med Oncol 2015;7:198-205. [PMID: 26136851 DOI: 10.1177/1758834015579313] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
110 El-Kholy E, Khaled L. Diagnostic Accuracy of Dual-Time-Point Fluorodeoxyglucose-Positron Emission Tomography/Computed Tomography in Verification Local Recurrence in Pancreatic Cancer Patients. Indian J Nucl Med 2019;34:271-7. [PMID: 31579197 DOI: 10.4103/ijnm.IJNM_97_19] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
111 Riall TS. What is the effect of age on pancreatic resection? Adv Surg. 2009;43:233-249. [PMID: 19845182 DOI: 10.1016/j.yasu.2009.02.004] [Cited by in Crossref: 56] [Cited by in F6Publishing: 48] [Article Influence: 4.3] [Reference Citation Analysis]
112 Gradiz R, Silva HC, Carvalho L, Botelho MF, Mota-Pinto A. MIA PaCa-2 and PANC-1 - pancreas ductal adenocarcinoma cell lines with neuroendocrine differentiation and somatostatin receptors. Sci Rep 2016;6:21648. [PMID: 26884312 DOI: 10.1038/srep21648] [Cited by in Crossref: 65] [Cited by in F6Publishing: 61] [Article Influence: 10.8] [Reference Citation Analysis]
113 Thobie A, Mulliri A, Bouvier V, Launoy G, Alves A, Dejardin O. Same Chance of Accessing Resection? Impact of Socioeconomic Status on Resection Rates Among Patients with Pancreatic Adenocarcinoma-A Systematic Review. Health Equity 2021;5:143-50. [PMID: 33778318 DOI: 10.1089/heq.2019.0099] [Reference Citation Analysis]
114 Benjamin AJ, Buschmann MM, Schneider A, Derstine BA, Friedman JF, Wang SC, Dale W, Roggin KK. Can Comprehensive Imaging Analysis with Analytic Morphomics and Geriatric Assessment Predict Serious Complications in Patients Undergoing Pancreatic Surgery? J Gastrointest Surg 2017;21:1009-16. [PMID: 28342121 DOI: 10.1007/s11605-017-3392-3] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
115 Revels SL, Banerjee M, Yin H, Sonnenday CJ, Birkmeyer JD. Racial disparities in surgical resection and survival among elderly patients with poor prognosis cancer. J Am Coll Surg 2013;216:312-9. [PMID: 23195204 DOI: 10.1016/j.jamcollsurg.2012.09.019] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 2.6] [Reference Citation Analysis]
116 Lee SH, Kang CM, Hwang HK, Choi SH, Lee WJ, Chi HS. Minimally invasive RAMPS in well-selected left-sided pancreatic cancer within Yonsei criteria: long-term (>median 3 years) oncologic outcomes. Surg Endosc. 2014;28:2848-2855. [PMID: 24853839 DOI: 10.1007/s00464-014-3537-3] [Cited by in Crossref: 70] [Cited by in F6Publishing: 61] [Article Influence: 8.8] [Reference Citation Analysis]
117 Shia BC, Qin L, Lin KC, Fang CY, Tsai LL, Kao YW, Wu SY. Age comorbidity scores as risk factors for 90-day mortality in patients with a pancreatic head adenocarcinoma receiving a pancreaticoduodenectomy: A National Population-Based Study. Cancer Med 2020;9:562-74. [PMID: 31789464 DOI: 10.1002/cam4.2730] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
118 Dimou F, Sineshaw H, Parmar AD, Tamirisa NP, Jemal A, Riall TS. Trends in Receipt and Timing of Multimodality Therapy in Early-Stage Pancreatic Cancer. J Gastrointest Surg 2016;20:93-103; discussion 103. [PMID: 26503262 DOI: 10.1007/s11605-015-2952-7] [Cited by in Crossref: 27] [Cited by in F6Publishing: 29] [Article Influence: 3.9] [Reference Citation Analysis]
119 Arima K, Hashimoto D, Okabe H, Inoue R, Kaida T, Higashi T, Taki K, Nitta H, Hayashi H, Chikamoto A, Beppu T, Baba H. Intraoperative blood loss is not a predictor of prognosis for pancreatic cancer. Surg Today 2016;46:792-7. [PMID: 26302976 DOI: 10.1007/s00595-015-1238-8] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.9] [Reference Citation Analysis]
120 Shah A, Chao KS, Ostbye T, Castleberry AW, Pietrobon R, Gloor B, Clary BM, White RR, Worni M. Trends in racial disparities in pancreatic cancer surgery. J Gastrointest Surg 2013;17:1897-906. [PMID: 24002757 DOI: 10.1007/s11605-013-2304-4] [Cited by in Crossref: 33] [Cited by in F6Publishing: 33] [Article Influence: 3.7] [Reference Citation Analysis]
121 Omari J, Heinze C, Wilck A, Hass P, Seidensticker M, Seidensticker R, Mohnike K, Ricke J, Pech M, Powerski M. Efficacy and safety of CT-guided high-dose-rate interstitial brachytherapy in primary and secondary malignancies of the pancreas. Eur J Radiol 2019;112:22-7. [PMID: 30777214 DOI: 10.1016/j.ejrad.2018.12.020] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
122 Galloway NR, Aspe JR, Sellers C, Wall NR. Enhanced antitumor effect of combined gemcitabine and proton radiation in the treatment of pancreatic cancer. Pancreas 2009;38:782-90. [PMID: 19506533 DOI: 10.1097/MPA.0b013e3181a85999] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
123 Jiang J, Ye S, Xu Y, Chang L, Hu X, Ru G, Guo Y, Yi X, Yang L, Huang D. Circulating Tumor DNA as a Potential Marker to Detect Minimal Residual Disease and Predict Recurrence in Pancreatic Cancer. Front Oncol 2020;10:1220. [PMID: 32850360 DOI: 10.3389/fonc.2020.01220] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
124 Habermehl D, Kessel K, Welzel T, Hof H, Abdollahi A, Bergmann F, Rieken S, Weitz J, Werner J, Schirmacher P. Neoadjuvant chemoradiation with Gemcitabine for locally advanced pancreatic cancer. Radiat Oncol. 2012;7:28. [PMID: 22385572 DOI: 10.1186/1748-717x-7-28] [Cited by in Crossref: 67] [Cited by in F6Publishing: 34] [Article Influence: 6.7] [Reference Citation Analysis]
125 Lindsey BD, Kim J, Dayton PA, Jiang X. Dual-Frequency Piezoelectric Endoscopic Transducer for Imaging Vascular Invasion in Pancreatic Cancer. IEEE Trans Ultrason Ferroelectr Freq Control 2017;64:1078-86. [PMID: 28489536 DOI: 10.1109/TUFFC.2017.2702010] [Cited by in Crossref: 17] [Cited by in F6Publishing: 11] [Article Influence: 3.4] [Reference Citation Analysis]
126 Del Valle JP, Fillmore NR, Molina G, Fairweather M, Wang J, Clancy TE, Ashley SW, Urman RD, Whang EE, Gold JS. Socioeconomic Disparities in Pancreas Cancer Resection and Survival in the Veterans Health Administration. Ann Surg Oncol. [DOI: 10.1245/s10434-021-11250-0] [Reference Citation Analysis]
127 DePeralta DK, Ogami T, Zhou JM, Schell MJ, Powers BD, Hodul PJ, Malafa MP, Fleming JB. Completion of adjuvant therapy in patients with resected pancreatic cancer. HPB (Oxford) 2020;22:241-8. [PMID: 31563326 DOI: 10.1016/j.hpb.2019.07.008] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
128 Raigani S, Ammori J, Kim J, Hardacre JM. Trends in the treatment of resectable pancreatic adenocarcinoma. J Gastrointest Surg 2014;18:113-23. [PMID: 24002769 DOI: 10.1007/s11605-013-2335-x] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 2.3] [Reference Citation Analysis]
129 Imada R, Komakata T, Aryal B, Tada N, Nuruki K, Kataoka T, Hiramine K, Mukaihara K, Kinjo T. Pancreaticoduodenectomy after transcatheter aortic valve implantation in an elderly patient with severe aortic stenosis and pancreas cancer: A case report. Ann Med Surg (Lond) 2021;62:207-10. [PMID: 33537131 DOI: 10.1016/j.amsu.2021.01.050] [Reference Citation Analysis]
130 Werner J, Combs SE, Springfeld C, Hartwig W, Hackert T, Büchler MW. Advanced-stage pancreatic cancer: therapy options. Nat Rev Clin Oncol. 2013;10:323-333. [PMID: 23629472 DOI: 10.1038/nrclinonc.2013.66] [Cited by in Crossref: 133] [Cited by in F6Publishing: 124] [Article Influence: 14.8] [Reference Citation Analysis]
131 Nipp R, Tramontano AC, Kong CY, Pandharipande P, Dowling EC, Schrag D, Hur C. Disparities in cancer outcomes across age, sex, and race/ethnicity among patients with pancreatic cancer. Cancer Med 2018;7:525-35. [PMID: 29322643 DOI: 10.1002/cam4.1277] [Cited by in Crossref: 45] [Cited by in F6Publishing: 49] [Article Influence: 11.3] [Reference Citation Analysis]
132 Carroll JE, Smith JK, Simons JP, Murphy MM, Ng SC, Shah SA, Zhou Z, Tseng JF. Redefining mortality after pancreatic cancer resection. J Gastrointest Surg 2010;14:1701-8. [PMID: 20844977 DOI: 10.1007/s11605-010-1326-4] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 1.8] [Reference Citation Analysis]
133 Wiseman JT, Chakedis J, Beal EW, Paredes A, McElhany A, Fang A, Manilchuk A, Ellison C, Van Buren G, Pawlik TM, Schmidt CR, Fisher WE, Dillhoff M. Hemoglobin A1c Is a Predictor of New Insulin Dependence After Partial Pancreatectomy: A Multi-Institutional Analysis. J Gastrointest Surg 2021. [PMID: 33948858 DOI: 10.1007/s11605-021-05014-0] [Reference Citation Analysis]
134 Assifi MM, Lu X, Eibl G, Reber HA, Li G, Hines OJ. Neoadjuvant therapy in pancreatic adenocarcinoma: a meta-analysis of phase II trials. Surgery. 2011;150:466-473. [PMID: 21878232 DOI: 10.1016/j.surg.2011.07.006] [Cited by in Crossref: 138] [Cited by in F6Publishing: 122] [Article Influence: 12.5] [Reference Citation Analysis]
135 Bilimoria KY, Stewart AK, Winchester DP, Ko CY. The National Cancer Data Base: a powerful initiative to improve cancer care in the United States. Ann Surg Oncol 2008;15:683-90. [PMID: 18183467 DOI: 10.1245/s10434-007-9747-3] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
136 Mirkin KA, Hollenbeak CS, Wong J. Time to Surgery: a Misguided Quality Metric in Early Stage Pancreatic Cancer. J Gastrointest Surg 2018;22:1365-75. [PMID: 29520648 DOI: 10.1007/s11605-018-3730-0] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
137 Principe DR, Underwood PW, Korc M, Trevino JG, Munshi HG, Rana A. The Current Treatment Paradigm for Pancreatic Ductal Adenocarcinoma and Barriers to Therapeutic Efficacy. Front Oncol 2021;11:688377. [PMID: 34336673 DOI: 10.3389/fonc.2021.688377] [Reference Citation Analysis]
138 Tavakkoli A, Singal AG, Waljee AK, Scheiman JM, Murphy CC, Pruitt SL, Xuan L, Kwon RS, Law RJ, Elta GH, Wright-Slaughter P, Valley TS, Kubiliun N, Nathan H, Rubenstein JH, Elmunzer BJ. Regional and racial variations in the utilization of endoscopic retrograde cholangiopancreatography among pancreatic cancer patients in the United States. Cancer Med 2019;8:3420-7. [PMID: 31087545 DOI: 10.1002/cam4.2225] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
139 Pastrana Del Valle J, Mahvi DA, Fairweather M, Wang J, Clancy TE, Ashley SW, Urman RD, Whang EE, Gold JS. Associations of gender, race, and ethnicity with disparities in short-term adverse outcomes after pancreatic resection for cancer. J Surg Oncol 2021. [PMID: 34786728 DOI: 10.1002/jso.26748] [Reference Citation Analysis]
140 Kokumai T, Aoki S, Mizuma M, Maeda S, Ohtsuka H, Nakagawa K, Morikawa T, Motoi F, Kamei T, Unno M. Prognostic value of an inflammation-based nutritional score for patients with initially unresectable pancreatic adenocarcinoma undergoing conversion surgery following chemo-/radiotherapy. Surg Today 2021. [PMID: 33829334 DOI: 10.1007/s00595-021-02279-5] [Reference Citation Analysis]
141 Gillen S, Schuster T, Meyer Zum Büschenfelde C, Friess H, Kleeff J. Preoperative/neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of response and resection percentages. PLoS Med 2010;7:e1000267. [PMID: 20422030 DOI: 10.1371/journal.pmed.1000267] [Cited by in Crossref: 923] [Cited by in F6Publishing: 846] [Article Influence: 76.9] [Reference Citation Analysis]
142 Bilimoria KY, Stewart AK, Winchester DP, Ko CY. The National Cancer Data Base: a powerful initiative to improve cancer care in the United States. Ann Surg Oncol 2008;15:683-90. [PMID: 18183467 DOI: 10.1245/s10434-007-9747-3] [Cited by in Crossref: 1127] [Cited by in F6Publishing: 1140] [Article Influence: 80.5] [Reference Citation Analysis]
143 Ho V, Ku-Goto MH, Zhao H, Hoffman KE, Smith BD, Giordano SH. Regional differences in recommended cancer treatment for the elderly. BMC Health Serv Res 2016;16:262. [PMID: 27417075 DOI: 10.1186/s12913-016-1534-z] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
144 Kayaoğlu HA, Çaycı HM, Erdoğdu UE, Dilektaşlı E, Bayam ME, Çantay H. Laparoscopic pancreaticoduodenectomy in pancreatic cancer: Our initial experience. Turk J Surg 2018;34:323-6. [PMID: 30664433 DOI: 10.5152/UCD.2017.3514] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
145 Iacobuzio-Donahue CA, Fu B, Yachida S, Luo M, Abe H, Henderson CM, Vilardell F, Wang Z, Keller JW, Banerjee P. DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer. J Clin Oncol. 2009;27:1806-1813. [PMID: 19273710 DOI: 10.1200/jco.2008.17.7188] [Cited by in Crossref: 704] [Cited by in F6Publishing: 405] [Article Influence: 54.2] [Reference Citation Analysis]
146 Pandé R, Hodson J, Murray A, Marcon F, Kalisvaart M, Marudanayagam R, Sutcliffe RP, Mirza DF, Isaac J, Roberts KJ. Evaluation of the clinical and economic impact of delays to surgery in patients with periampullary cancer. BJS Open 2019;3:476-84. [PMID: 31388640 DOI: 10.1002/bjs5.50161] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
147 Arslan C, Yalcin S. Current and future systemic treatment options in metastatic pancreatic cancer. J Gastrointest Oncol. 2014;5:280-295. [PMID: 25083302 DOI: 10.3978/j.issn.2078-6891.2014.030] [Cited by in F6Publishing: 17] [Reference Citation Analysis]
148 Zhu D, Wang L, Zhang H, Chen J, Wang Y, Byanju S, Liao M. Prognostic value of 18F-FDG-PET/CT parameters in patients with pancreatic carcinoma: A systematic review and meta-analysis. Medicine (Baltimore) 2017;96:e7813. [PMID: 28816978 DOI: 10.1097/MD.0000000000007813] [Cited by in Crossref: 18] [Cited by in F6Publishing: 9] [Article Influence: 3.6] [Reference Citation Analysis]
149 Tzeng CD, Cao HST, Lee JE, Pisters PWT, Varadhachary GR, Wolff RA, Abbruzzese JL, Crane CH, Evans DB, Wang H, Abbott DE, Vauthey J, Aloia TA, Fleming JB, Katz MHG. Treatment Sequencing for Resectable Pancreatic Cancer: Influence of Early Metastases and Surgical Complications on Multimodality Therapy Completion and Survival. J Gastrointest Surg 2014;18:16-25. [DOI: 10.1007/s11605-013-2412-1] [Cited by in Crossref: 121] [Cited by in F6Publishing: 107] [Article Influence: 13.4] [Reference Citation Analysis]
150 Ward EP, Zeh Iii HJ, Tsai S. Current Controversies in Neoadjuvant Therapy for Pancreatic Cancer. Surg Oncol Clin N Am 2021;30:657-71. [PMID: 34511188 DOI: 10.1016/j.soc.2021.06.010] [Reference Citation Analysis]
151 Ruess DA, Biesel EA, Kühlbrey CM, Chikhladze S, Hipp J, Lünstedt J, Fichtner-feigl S, Hopt UT, Wittel UA. Pancreatic Resection in Older Patients: A Retrospective Single-Center Outcome Analysis. Surgeries 2020;1:30-45. [DOI: 10.3390/surgeries1010005] [Reference Citation Analysis]
152 Perini MV, Montagnini AL, Jukemura J, Penteado S, Abdo EE, Patzina R, Cecconello I, Cunha JE. Clinical and pathologic prognostic factors for curative resection for pancreatic cancer. HPB (Oxford). 2008;10:356-362. [PMID: 18982152 DOI: 10.1080/13651820802140752] [Cited by in Crossref: 30] [Cited by in F6Publishing: 29] [Article Influence: 2.5] [Reference Citation Analysis]
153 Quero G, Salvatore L, Fiorillo C, Bagalà C, Menghi R, Maria B, Cina C, Laterza V, Di Stefano B, Maratta MG, Ribelli M, Galiandro F, Mattiucci GC, Brizi MG, Genco E, D'Aversa F, Zileri L, Attili F, Larghi A, Perri V, Inzani F, Gasbarrini A, Valentini V, Costamagna G, Manfredi R, Tortora G, Alfieri S. The impact of the multidisciplinary tumor board (MDTB) on the management of pancreatic diseases in a tertiary referral center. ESMO Open 2021;6:100010. [PMID: 33399076 DOI: 10.1016/j.esmoop.2020.100010] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
154 McDowell BD, Chapman CG, Smith BJ, Button AM, Chrischilles EA, Mezhir JJ. Pancreatectomy predicts improved survival for pancreatic adenocarcinoma: results of an instrumental variable analysis. Ann Surg. 2015;261:740-745. [PMID: 24979599 DOI: 10.1097/sla.0000000000000796] [Cited by in Crossref: 32] [Cited by in F6Publishing: 17] [Article Influence: 4.6] [Reference Citation Analysis]
155 Boyd CA, Benarroch-Gampel J, Sheffield KM, Han Y, Kuo YF, Riall TS. The effect of depression on stage at diagnosis, treatment, and survival in pancreatic adenocarcinoma. Surgery 2012;152:403-13. [PMID: 22938900 DOI: 10.1016/j.surg.2012.06.010] [Cited by in Crossref: 37] [Cited by in F6Publishing: 36] [Article Influence: 3.7] [Reference Citation Analysis]
156 Kanda T, Wakiya T, Ishido K, Kimura N, Nagase H, Kubota S, Fujita H, Hagiwara Y, Hakamada K. Intraoperative Allogeneic Red Blood Cell Transfusion Negatively Influences Prognosis After Radical Surgery for Pancreatic Cancer: A Propensity Score Matching Analysis. Pancreas 2021;50:1314-25. [PMID: 34860818 DOI: 10.1097/MPA.0000000000001913] [Reference Citation Analysis]
157 Boevers E, McDowell BD, Mott SL, Button AM, Lynch CF. Insurance Status Is Related to Receipt of Therapy and Survival in Patients with Early-Stage Pancreatic Exocrine Carcinoma. J Cancer Epidemiol 2017;2017:4354592. [PMID: 28487737 DOI: 10.1155/2017/4354592] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.2] [Reference Citation Analysis]
158 Buanes TA. Pancreatic cancer-improved care achievable. World J Gastroenterol 2014; 20(30): 10405-10418 [PMID: 25132756 DOI: 10.3748/wjg.v20.i30.10405] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.9] [Reference Citation Analysis]
159 Khattab A, Patruni S, Abel S, Hasan S, Ludmir EB, Finley G, Monga D, Wegner RE, Verma V. Long-term outcomes by response to neoadjuvant chemotherapy or chemoradiation in patients with resected pancreatic adenocarcinoma. J Gastrointest Oncol 2019;10:918-27. [PMID: 31602330 DOI: 10.21037/jgo.2019.07.02] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
160 Visser BC, Ma Y, Zak Y, Poultsides GA, Norton JA, Rhoads KF. Failure to comply with NCCN guidelines for the management of pancreatic cancer compromises outcomes. HPB (Oxford). 2012;14:539-547. [PMID: 22762402 DOI: 10.1111/j.1477-2574.2012.00496.x] [Cited by in Crossref: 79] [Cited by in F6Publishing: 68] [Article Influence: 7.9] [Reference Citation Analysis]
161 Watson MD, Miller-Ocuin JL, Driedger MR, Beckman MJ, McKillop IH, Baker EH, Martinie JB, Vrochides D, Iannitti DA, Ocuin LM. Factors Associated with Treatment and Survival of Early Stage Pancreatic Cancer in the Era of Modern Chemotherapy: An Analysis of the National Cancer Database. J Pancreat Cancer 2020;6:85-95. [PMID: 32999955 DOI: 10.1089/pancan.2020.0011] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
162 Kim ST, Kim SY, Lee J, Kim K, Park SH, Park YS, Lim HY, Kang WK, Park JO. Triptolide as a novel agent in pancreatic cancer: the validation using patient derived pancreatic tumor cell line. BMC Cancer 2018;18:1103. [PMID: 30419860 DOI: 10.1186/s12885-018-4995-0] [Cited by in Crossref: 8] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
163 Raju RS, Coburn N, Liu N, Porter JM, Seung SJ, Cheung MC, Goyert N, Leighl NB, Hoch JS, Trudeau ME, Evans WK, Dainty KN, Earle CC, Mittmann N. A population-based study of the epidemiology of pancreatic cancer: a brief report. Curr Oncol 2015;22:e478-84. [PMID: 26715886 DOI: 10.3747/co.22.2653] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 2.4] [Reference Citation Analysis]
164 D'Haese JG, Werner J. [Resectability of pancreatic cancer: New criteria]. Radiologe 2016;56:318-24. [PMID: 26993121 DOI: 10.1007/s00117-016-0092-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
165 Rahman SH, Urquhart R, Molinari M. Neoadjuvant therapy for resectable pancreatic cancer. World J Gastrointest Oncol 2017; 9(12): 457-465 [PMID: 29290916 DOI: 10.4251/wjgo.v9.i12.457] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
166 Hsieh MC, Chang WW, Yu HH, Lu CY, Chang CL, Chow JM, Chen SU, Cheng Y, Wu SY. Adjuvant radiotherapy and chemotherapy improve survival in patients with pancreatic adenocarcinoma receiving surgery: adjuvant chemotherapy alone is insufficient in the era of intensity modulation radiation therapy. Cancer Med. 2018;7:2328-2338. [PMID: 29665327 DOI: 10.1002/cam4.1479] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
167 Zhan HX, Xu JW, Wu D, Wu ZY, Wang L, Hu SY, Zhang GY. Neoadjuvant therapy in pancreatic cancer: a systematic review and meta-analysis of prospective studies. Cancer Med. 2017;6:1201-1219. [PMID: 28544758 DOI: 10.1002/cam4.1071] [Cited by in Crossref: 72] [Cited by in F6Publishing: 70] [Article Influence: 14.4] [Reference Citation Analysis]
168 Anderson B, Karmali S. Laparoscopic resection of pancreatic adenocarcinoma: Dream or reality? World J Gastroenterol 2014; 20(39): 14255-14262 [PMID: 25339812 DOI: 10.3748/wjg.v20.i39.14255] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 16] [Article Influence: 1.9] [Reference Citation Analysis]
169 Royal RE, Levy C, Turner K, Mathur A, Hughes M, Kammula US, Sherry RM, Topalian SL, Yang JC, Lowy I, Rosenberg SA. Phase 2 trial of single agent Ipilimumab (anti-CTLA-4) for locally advanced or metastatic pancreatic adenocarcinoma. J Immunother. 2010;33:828-833. [PMID: 20842054 DOI: 10.1097/cji.0b013e3181eec14c] [Cited by in Crossref: 572] [Cited by in F6Publishing: 423] [Article Influence: 52.0] [Reference Citation Analysis]